Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?

Lancet Diabetes Endocrinol. 2020 Oct;8(10):810-811. doi: 10.1016/S2213-8587(20)30302-8.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Glucose / metabolism*
  • Cardiovascular Diseases / prevention & control*
  • Diabetes Complications / prevention & control*
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / epidemiology
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Patient Safety*
  • Practice Guidelines as Topic / standards*
  • Risk Assessment
  • Risk Factors
  • United States
  • United States Food and Drug Administration

Substances

  • Blood Glucose
  • Hypoglycemic Agents